Introduction
The emergence of multidrug resistant (MDR) strains of MTBC has become one of the most critical issues for tuberculosis (TB) control programmes worldwide. It is a public health concern threatening global TB control programs. Its diagnosis has evolved in recent years following the development of new molecular techniques based on detection of mutations in MTBC genes by Polymerase Chain Reaction (PCR). [1] [2] [3] The Genotype MTBDRplus is a commercially available molecular gene Line Probe Assay developed by Hain Life Science, (Nehren, Germany). It is performed on MTBC isolates or directly from clinical specimens. It able to identify the MTBC and detect the genetic mutations in the rpoB gene related to rifampicin resistance, the katG, inhA regulatory region and inhA genes related to isoniazid resistance. Its targets points are the 81-bp "hot spot" region of the rpoB gene of RIF, codon 315 of katG and inhA promoter regions of INH. [4] [5] [6] [7] The genetic basis of multidrug resistant MTB isolates has been widely studied worldwide and commonly believed to be caused by point mutations in important genes like rpoB and katG. Multiple studies carried out at different time periods in the same country/geographical setting have yielded variable incidence of specific rpoB mutation. 8, 9 In Burkina Faso, the fight against MDR-TB/rifampicin-resistant tuberculosis (RR-TB) has become a National concern. For this purpose, the technical platform of the National Reference Laboratory (NRL) for Mycobacteria in Ouagadougou was strengthened with Molecular tests such as Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) and selected for the Molecular analysis at the NRL. DNA was extracted using Genolyse ® kit (Hain Life Science GmbH, Nehren, Germany). The extracted DNA was processed by the LPA using DRplus (Hain Life Science GmbH, Nehren, Germany) to detect MTBC and RIF and/or INH resistance according to the manufacturer's instructions. 7 PCR amplification was carried out using biotin-labeled primers. The colorimetric detection of the strips was carried out using enzymes in which DNA products were bound to the strip. Positive internal quality control and negative control were used during the tests. The rpoB, katG, and inhA gene loci each have a control band, the presence of which is mandatory for results interpretation. The presence of rpoB gene locus predicts RIF's resistance while katG predicts high level and inhA low-level INH resistance. Absence of wild type and/or presence of mutant band mean resistance to a particular drug. The product insert was further referred for interpretation of banding patterns and trouble shooting.
Limitation of the study
We have not reported the occurrence of katG and rpoB mutations in INH and RMP resistant M. tuberculosis isolates from patients of different ethnic background from Burkina Faso. Secondly, among the isolates studied, we do not know which Beijing genotype strains are or not. These two limits did not allow us to understand the higher frequencies of certain mutations compared to the studies that studied them. Thirdly, only DRplus was used to study the occurrence genes mutations.
Statistical analysis
The results obtained were entered into Statistical Program SPSS version 20.0 and the frequency of patient characteristics and mutations in the rpoB, katG and inhA genes calculated
Results

Patients' characteristics
One hundred and ten (110) TB patients with resistant to rifampicin by Xpert test (27 females and 83 males) were included. The average age for female patients was 39.9 years (14-70 years), while the male was 36.5 years (16-86 years). Two (2) females and 6 males were tested HIV positive and 26 females and 79 males had a history of TB treatment or were undergoing TB treatment ( Table 1) . DRplus revealed 76 patients who were resistant to rifampicin, 83 to isoniazid. Among the females, 27 patients were resistant each to rifampicin and isoniazid while 24 were resistant to both isoniazid and rifampicin respectively. The results of Xpert test and DRplus were discordant for 7 patients. This is as presented in Table 1 .
Occurrence of mutations in isoniazid and rifampicin resistance associated targets
In Table 2 , out of the 103 isolates with RIF resistant, single mutations were observed in the codons D516V (41.7%), followed by H526Y (17.5%) and then S531L (5.8%). Double mutations in rpoB gene were observed in 6 of the codons D516V+S531L (5.8%), 3 of D516V+H526Y (2.9%) and 1 of D516V+H526D respectively. The occurrence of single and combine mutations in rpoB gene where found to be 51.5% in the codons D516V, 20.4% in H526Y, 11.7% in S531L and 10.7% in H526D respectively while no mutation was found in 16 (15.5%) other cases, even though the wild probes had disappeared. The mutations responsible for high-level isoniazid resistance in katG gene were observed in the codons S315T1 (77.3%), S315T2 (2.7%), unknown (3.6%) while combined high-level isoniazid resistance mutations in katG and inhA gene where observed in the codons C8T+S315T (14.5%) respectively. The mutations responsible for a low level of resistance to isoniazid in inhA were observed in the codons C8T+C15T (0.9%) with unknown mutation (0.9%).
Occurrence of codon mutations in rifampicin and isoniazid resistant isolates from different countries/ geographical settings
The comparison of the occurrence of codon mutations in rifampicin and isoniazid resistant MTBC isolates from different geographic regions is presented in Table 3 mutations in the rpoB gene was found in the codons 516, 526 and 531 varied in different geographic regions (Table 3 ). It is the same for the occurrence of mutations in the katG gene and inhA gene promoter (Table 4 ). 
Discussion
This study evaluated the occurrence of mutations in the rpoB, katG, and inhA gene promoters responsible for the resistance of M. tuberculosis complex to rifampicin and isoniazid in patients detected RR-TB by Xpert MTB/RIF. It revealed mutations in the rpoB gene most commonly at codons D516V, H526Y and S531L. The codon 516 (51.5%) had the highest mutations in the rpoB genes. Such a high occurrence agrees with the reports of previous studies in Burkina Faso and other parts of the world; such as 10 who reported 43.7% in Burkina Faso 11 who reported 46.2% in Ghana. 12 It is possible that the epidemiology of TB is identical for these Countries. However, the finding was at variance with 5,13,14 who reported a low occurrence of 2.1%, 20.0% and 21.1% respectively. Regional variation in the epidemiology of TB could be accounted for these discrepancies.
On the other hand, studies carried out in South West Ethiopia and in Basil have not found a mutation at codon 516. 15, 16 The occurrence of 531 mutations (11.7%) in this study was comparable to 9.4% found in the previous study. 10 Our finding and those of Burkina Faso neighboring countries 11, [12] [13] [14] contrast enormously with the results of numerous studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] which reported higher rates of mutations at 531. High rates of 531 mutations were particularly found in Kyrgyzstan, Ethiopia, Brasil, South West Ethiopia, Georgia, Taiwan and Samara in Russia. 21, [23] [24] [25] [26] [27] [28] Some authors attributed the variations in the frequency of rpoB-specific mutations to the geographical differences in RMPresistant M. tuberculosis strains circulating in different settings and their clone propagation. 28, 30 So, for Taiwan, codon 531 accounted for 68.2% of mutations could be due to the spread of a prevalent genetic clone. 26 The high occurrence of rpoB531 mutation in MDR-TB strains from Samara region in Russian Federation was attributed to the high frequency of Beijing genotype strains, 28 but that's not a certainty. For instance, the frequency of rpoB531 mutations is much lower in RMPresistant strains in China where the frequency of the Beijing genotype strains is high. 31 The occurrence of mutation at 526 reported in the current study is higher than rate found in Burkina Faso neighbouring Countries, 11, [12] [13] [14] lower than the value reported in Nigeria 6 and similar to findings reported from India and Kyrgyzstan. 2, 21 All this indicates that mutations at codons 531, 526 and 516 are common, with a varied occurrence across the geographical areas.
In this study, occurrence of gene mutation attributed to low level drug resistance mainly caused by the mutations in the promoter region of inhA gene was lower than the mutation frequent C15T observed in Ivory Coast. 13 Occurrence of katG315 mutations was lower than those obtained in Ghana and in Southwest Ethiopia, 11, 25 similar to an Ivorian study 12 , and higher than a report from Nigerian. 6 The high occurrence (90-95%) of katG315 mutations among M. tuberculosis strains in Russia was attributed to the high frequency of Beijing genotype strains. 32, 33 However, the frequency of katG315 mutations is much lower in INH resistant strains in Taiwan, where the frequency of the Beijing genotype strains is high. 34, 35 Some authors reported variations of the occurrence of katG315 mutations in isoniazid-resistant isolates among patients of different ethnic groups at the same geographic locations. 8 It remains to be elucidated whether these differences of variations are due to differences in the genetic background of M. tuberculosis isolates or to differences in ethnic origin of the infected TB patients or both.
Our study showed higher level of rifampicin-resistant isolates with no mutation. It corroborated with similar reports from elsewhere. 17, 36, 37 It is possible that less common mutations in rpoB gene cannot be detected by DRplus. 21 In addition, the possibilities of absence of mutation in RRDR of rpoB gene in MDR-TB isolates may be due to existence of other rare rpoB mutations outside RRDR or different mechanism of rifampicin resistance. 38 For strains classified as isoniazid-resistant with no mutation, it is known that about 10% to 25% of isoniazid-resistance strains are thought to have mutations outside KatG and inhA loci. Efflux system may play such a role. 39, 40 To cater the geographic specificity of the target genes and be able to detect more possible mutations in different geographical areas, it is necessary to improve molecular assay kit diagnosis. 41, 42 
Conclusions
In Burkina Faso, the general pattern of rpoB, katG and inhA mutations observed is similar to that reported globally in most clinical M. tuberculosis isolates. The highest mutation occurrence was observed respectively at 516 and 526 of rpoB, and katG (S315T1) genes. However, the DRplus, did not identify certain mutations while the wild probes had disappeared. So, the mutations identified are useful as molecular markers for the detection of multidrug resistant isolates but are not yet sufficient to fully predict a multidrug resistance of M. tuberculosis. Hence the need to improve molecular assay kit diagnosis to cater for the genetic variations associated with the geographic specificity of the target genes and be able to detect most frequent mutations in different geographical areas. Likewise, using phenotypic drug susceptibility testing and sequencing will allow identifying missing mutations not detected by the DRplus.
